SMILES string
N1(CCN(CCC1)c2[n](c3c(n2)cccc3)CCOCC)C.OC(=O)\C=C\C(=O)O.OC(=O)\C=C\C(=O)O
InChI
1S/C17H26N4O.2C4H4O4/c1-3-22-14-13-21-16-8-5-4-7-15(16)18-17(21)20-10-6-9-19(2)11-12-20;2*5-3(6)1-2-4(7)8/h4-5,7-8H,3,6,9-14H2,1-2H3;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1+
InChI key
FWLKKPKZQYVAFR-LVEZLNDCSA-N
grade
pharmaceutical primary standard
API family
emedastine
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
正在寻找类似产品? 访问 产品对比指南
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Emedastine difumarate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Yuan Tian et al.
Journal of chromatographic science, 45(3), 158-164 (2007-04-28)
A selective and sensitive method employing high-performance liquid chromatography (HPLC)-electrospray ionization (ESI)-mass spectrometry is developed and validated for the determination of emedastine difumarate in human plasma. With naphazoline hydrochloride as the internal standard, emedastine difumarate is extracted from plasma with
Annik Pons-Guiraud et al.
European journal of dermatology : EJD, 16(6), 649-654 (2007-01-19)
Emedastine difumarate (2 mg b.i.d.) was compared to loratadine (10 mg o.d.) in a randomized, double-blind, multicentre trial for 4 weeks in 192 patients with idiopathic chronic urticaria. After one week of treatment significant differences were recorded: body skin involvement
Mario E Corrado et al.
Arzneimittel-Forschung, 54(10), 660-665 (2004-11-24)
Emedastine is a new H1-receptor antagonist endowed with potent and selective antihistamine activity. The aim of this study was to evaluate the therapeutic efficacy and tolerability of emedastine difumarate (CAS 87233-62-3) in Caucasian patients in the treatment of seasonal allergic
Shoichi Harada et al.
Journal of pharmaceutical sciences, 94(1), 17-24 (2005-03-12)
Antihistamine effects of emedastine applied topically with three vehicles varying in their polarities were investigated in rats. The pharmacological effect of emedastine differed greatly depending on its concentration, treatment time, and vehicle. The antihistamine effect reached a plateau after approximately
M Brunner et al.
Xenobiotica; the fate of foreign compounds in biological systems, 32(9), 761-770 (2002-10-25)
1. In a mass balance study, six healthy male volunteers received a single oral dose of 4 mg (14)C-labelled emedastine difumarate. The pharmacokinetics of the total radioactivity and unchanged drug were assessed over 48 h. Urinary and faecal excretion were
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持